Mainstream

Ashvattha therapeutics presents positive interim phase 2 results for subcutaneous migaldendranib treatment for dme and wet amd at 2025 maculart meeting

Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting

Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting

Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD

Novel subcutaneous delivery may offer a more patient-friendly…Read More

You might also be interested in reading ClawdBot (now Moltbot) Generates 247% Profit in 24 Hours on Polymarket.

June 30, 2025
In Mainstream